Contemporary Management of HIV 2021

Download All
Gain expert insights on the latest data supporting contemporary HIV prevention and HIV treatment across settings, including patients who are newly diagnosed, virologically suppressed, or experiencing virologic failure with resistance, along with new and emerging ART strategies.
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Daniel R. Kuritzkes, MD
Shobha Swaminathan, MD

New Data From IAS 2021

Listen as expert faculty discuss key studies influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic, metabolic, and safety outcomes of 2DR with DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive and heavily treatment–experienced PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Eric S. Daar, MD Shobha Swaminathan, MD Released: September 8, 2021

Listen as expert faculty discuss key studies influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic, metabolic, and safety outcomes of 2DR with DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive and heavily treatment–experienced PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Eric S. Daar, MD Shobha Swaminathan, MD Released: September 14, 2021

Download this expert-authored slideset to review the most clinically relevant new data presented at IAS 2021 covering a wide range of HIV management topics, including HIV and COVID-19 outcomes, 2-drug ART, long-acting injectable ART, investigational ART, and TB treatment options.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Watch expert faculty present and discuss with one another some of the most clinically relevant data presented at IAS 2021, including results from studies on COVID-19 outcomes among PWH, 2-drug ART regimens, long-acting injectable ART, novel ART in development, and drug therapy for multidrug-resistant TB.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD Shobha Swaminathan, MD
Released: October 12, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue